ArticleJournal of Cancer2025
Integrative Analysis of Histone Deacetylases Reveals the Potential Role and Prognostic Value of HDAC7 in Hepatocellular Carcinoma.
Article in Journal of Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) represents a complex malignancy characterized by molecular mechanisms that remain incompletely elucidated, underscoring the necessity for identifying genetic markers. Members of the histone deacetylase (HDAC) family are integral to epigenetic regulation, influencing chromatin architecture and transcriptional activity, thereby modulating gene expression within eukaryotic cells. Dysregulation of HDACs has been implicated in the initiation of aberrant transcriptional programs, contributing to the oncogenesis and progression of various cancers, including HCC. Despite the extensive HDAC family, the specific roles of individual members in HCC are not well-defined. This study utilizes data derived from clinical specimens and comprehensive databases to demonstrate that histone deacetylases, particularly HDAC7, exhibit differential expression in HCC samples, which correlates with significant variations in prognosis and pathological staging. Furthermore, functional enrichment analyses of HDAC7 and its co-expressed genes indicate that HDAC7 may act as an oncogene by modulating the expression of genes associated with key tumorigenic pathways. The analysis of immune cell infiltration further elucidates the association between HDAC7 expression levels and various immune cell types. In summary, HDAC7 emerges as a potential biomarker for the prognosis and diagnosis of HCC, providing significant insights for future research and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.